Evaluation of sertraline in depressed or anxious HSCT patients?

Evaluation of sertraline effects on the time of engraftmen and ?serum levels of such inflammatory and anti-inflammatory factors ?as IL-6, CRP and IL-10 in depressed HSCT patients?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201310083210N4

Enrollment

Registered

2013-12-11

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression and anxiety. Depressive episode,Generalized anxiety disorder

Interventions

Intervention 1: Control group: Placebo 50 to 100 mg orally per day for 90 days. Intervention 2: Intervention group: sertraline 50 to 100mg orally per day for 90 days.

Placebo

Treatment - Drugs

Control group: Placebo 50 to 100 mg orally per day for 90 days

Intervention group: sertraline 50 to 100mg orally per day for 90 days

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 60 ?years for allo-HSCT and auto-HSCT; presence of depression ?or based on Hospital Anxiety & Depression Scale (HADS) ; ?Stable & normal renal and liver function and ; Ability for oral ?taking of medication . Exclusion criteria: Patients with ?baseline kidney dysfunction (GFR less than 60 mL/min) ;Patients with ?abnormal LFT (bilirubin & ?aminotransferases level of more than 2 normal) ; Patient with sepsis or uncontrolled ?infection at baseline ; Patients unable to take orally ; Non-?cooporable patients with mental dysfunctionality ; pregnant or ?lactating women ; HIV+ patients ; Patients who who have taken ?antidepressant medication later than a month ago ;Intolerance of Sertraline adverse ?effects. ?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: Baseline 2 ,4, 8 and 12 weeks after. Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.;Anxiety. Timepoint: Baseline 2 ,4, 8 and 12 weeks after. Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.;IL-10 Inflammatort biomarker. Timepoint: Baseline, 2 and 4weeks after. Method of measurement: serum level pg/ml.;IL-6 inflammatory biomarker. Timepoint: Baseline, 4 and 8 weeks after. Method of measurement: Serum level pg / mL.;Hs-CRP inflammatory biomarker. Timepoint: Baseline, 4 and 8 weeks after. Method of measurement: Serum level mg / dl.	—

Measure

Time frame

Depression. Timepoint: Baseline 2 ,4, 8 and 12 weeks after. Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.;Anxiety. Timepoint: Baseline 2 ,4, 8 and 12 weeks after. Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.;IL-10 Inflammatort biomarker. Timepoint: Baseline, 2 and 4weeks after. Method of measurement: serum level pg/ml.;IL-6 inflammatory biomarker. Timepoint: Baseline, 4 and 8 weeks after. Method of measurement: Serum level pg / mL.;Hs-CRP inflammatory biomarker. Timepoint: Baseline, 4 and 8 weeks after. Method of measurement: Serum level mg / dl.

—

Secondary

Measure	Time frame
Engraftment time. Timepoint: Daily until absolute neutrophil count (ANC) more than 500 and platelet more than 20000 for 3 consecutive days. Method of measurement: Cell blood count(CBC).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mehrpooya

Shahid Beheshti University of Medical Sciences

m_mehrpooya2003@yahoo.com+98 918 316 3926

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026